Pembrolizumab: Myositis, myasthenia gravis and myocarditis.
In: Reactions Weekly, Jg. 2011 (2024-06-08), Heft 1, S. 352-352
serialPeriodical
Zugriff:
A 79-year-old man developed myositis, myasthenia gravis (MG), and myocarditis (triple M syndrome) while being treated with pembrolizumab for stage IV nonsmall cell lung cancer. He experienced worsening dyspnea and physical examination revealed right ptosis. Further tests showed elevated troponin-I and creatine kinase levels, as well as ECG abnormalities. The patient was admitted to the ICU and received treatment for myocarditis and MG. He was discharged on a methylprednisolone taper and remained stable. The case was reported as an instance of pembrolizumab-induced triple M syndrome, which resulted in third-degree atrioventricular block, left bundle branch block, and complete heart block. [Extracted from the article]
Titel: |
Pembrolizumab: Myositis, myasthenia gravis and myocarditis.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 2011 (2024-06-08), Heft 1, S. 352-352 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-024-60587-4 |
Schlagwort: |
|
Sonstiges: |
|